By ONN Staff

Sunny Pharmtech recalls three lots of Cyclophosphamide for Injection after steel particulates were found, posing risks of thromboembolic events.

A study reveals only 18.3% of young adults with advanced cancer receive palliative care, highlighting a critical gap for oncology nurses to address.

New research identifies treatment initiation thresholds that impact 3-year metastasis risk in colorectal cancer patients across distinct pathways.

The FDA approved zidesamtinib for metastatic ROS1-positive NSCLC following prior kinase inhibitor therapy, offering hope for patients with resistance.

A Neurology study reveals breast cancer survivors have a high ischemic stroke risk within one year of diagnosis, linked to specific treatment regimens.

A 10-year study of 3,477 patients reveals focal therapy offers high survival and low metastasis for localized prostate cancer with few side effects.

Simone Payette-Capone, RN, discusses balancing protocol with patient care, managing GU trial logistics, and the research nurse's role as a "detective."

NATCO Pharma receives tentative U.S. FDA approval for a generic version of the PARP inhibitor olaparib (Lynparza) for oncology indications.

Kevin Brigle, PhD, ANP, discusses frontline quads, managing toxicities of bispecifics, and the evolving role of nursing in multiple myeloma treatment.

Linda Casey, RN, shares essential strategies for oncology nurses to protect vulnerable patients from the clinical risks of wildfire smoke exposure.

FDA approves gedatolisib with fulvestrant for adults with HR+/HER2- metastatic breast cancer following endocrine therapy progression.

The FDA has granted traditional approval to selpercatinib for adult and pediatric patients with RET fusion-positive solid tumors post-progression.

Czarina Cecilio, BSN, RN, shares roundtable insights on toxicity management, injection techniques, and the critical role of nursing education.

The WHO 2026 report warns of a global cancer surge by 2050, highlighting critical inequities and the need for people-centered oncology nursing care.

FDA expanded pembrolizumab and enfortumab vedotin-ejfv for all surgery-eligible adults with muscle-invasive bladder cancer following positive trial data.

FDA approves subcutaneous isatuximab-irfc for multiple myeloma indications, offering an efficient delivery alternative to intravenous administration.

FDA approves Ennumo (pegfilgrastim-pccg), a biosimilar to Neulasta, providing a new option for oncology nurses to manage chemotherapy-induced neutropenia.

ESMO GI 2026 data show patients under 50 receive more aggressive therapy yet face poorer survival, suggesting EOCRC is a distinct biological entity.

Study finds 86.5% of gastric/GEJ patients completed surgery after neoadjuvant chemo, significantly improving survival over those who did not.

Long-term data show watch-and-wait is viable for rectal cancer, with most regrowths salvageable despite adverse baseline MRI features.

Melissa Baker discusses SOPs in transplant care, gene therapy for sickle cell, and the essential role of nurses in clinical strategy and care planning.

A real-world study presented at ESMO GI shows fruquintinib is effective in mCRC, with the best outcomes in the third-line setting.

Pamela Plasket, RN, discusses the evolving role of oncology nurses as lung cancer patients survive longer on advanced therapies like BiTEs.

Oncology nurse navigator Diane Stanaway discusses photosensitivity, new sunscreen innovations, and debunking common myths for patients and survivors.

The FDA approved Tregzi, a precision-engineered cell therapy, to improve chronic GVHD-free survival in adults undergoing allogeneic transplant.

PROSPER data reveal that mogamulizumab provides rapid, sustained relief from skin symptoms and improves sleep for patients with MF and SS.

The FDA approved Azurity’s Aprepitant Injectable Emulsion, a polysorbate-80-free, ready-to-use IV option for preventing chemotherapy-induced nausea.

New research finds younger generations age faster biologically, increasing risks for early-onset lung, colorectal, and other solid tumor cancers.

Oncology nurse Diane Stanaway offers essential sun protection strategies as NJ prepares for the heat of the 2026 World Cup and rising skin cancer rates.

The FDA approved the BESREMi Pen for polycythemia vera, offering a simplified self-administration option to improve patient adherence and care.